Richard S. Levy - 07 Nov 2024 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role
Director
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
07 Nov 2024
Net transactions value
$0
Form type
4
Filing time
12 Nov 2024, 16:35:04 UTC
Previous filing
05 Nov 2024
Next filing
11 Apr 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Ordinary Share Options Exercise +1,303 +10% 14,200 07 Nov 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Units Award $0 +1,303 $0.000000 1,303 07 Nov 2024 Class A Ordinary Shares 1,303 Direct F1, F2
transaction KNSA Restricted Share Units Options Exercise $0 -1,303 -100% $0.000000 0 07 Nov 2024 Class A Ordinary Shares 1,303 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2 The RSUs vested immediately upon grant on November 7, 2024; there was no expiration date for the RSUs.